Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5362_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Carbon Based Nanomaterials for Drug Delivery
- •Preface
- •Acknowledgements
- •Contents
- •Editor and Contributors
- •Abbreviations
- •1.2 Market Statistics
- •Carbon-Based Nanomaterials: An Overview
- •1. Introduction
- •1.1 Evolution of Carbon-Based Nanomaterials
- •2. Carbon-Based Nanostructures
- •2.1 Fullerene
- •2.2 Carbon Nanotubes (CNTs)
- •2.4 Graphene
- •2.5 Nanodiamonds (NDs)
- •2.6 Nano-Onions (CNOs)
- •2.7 Nanohorns (CNHs)
- •2.8 Carbon Dots (CDs)
- •2.9 Nanoporous Activated Carbon
- •3. Synthesis Techniques
- •4. Properties of Carbon-Based Nanomaterials
- •4.1 Physicochemical Properties
- •4.2 Thermal Properties
- •4.3 Mechanical Properties
- •4.4 Optoelectronic Properties
- •4.5 Antimicrobial Properties
- •4.6 Biological Properties
- •5. Applications of Carbon-Based Nanomaterials
- •5.1 Environmental Remediation
- •5.2 Agriculture
- •5.3 Biofuel
- •5.4 Energy Storage
- •5.5 Biomedical Applications
- •6. Challenges and Future Perspectives
- •7. Concluding Remarks
- •References
- •Carbon-Based Nanostructured Materials: Designing, Properties and Applications
- •1. Introduction
- •2.1 Zero-Dimensional Carbon-Based Nanostructures (0D)
- •2.2 One-Dimensional Carbon-Based Nanostructures
- •2.3 Two-Dimensional (2D) Carbon-Based Nanostructures
- •2.4 Three-Dimensional (3D) Carbon-Based Nanostructures
- •3.1 Chemical Vapor Deposition
- •3.2 Hydrothermal and Solvothermal Techniques
- •3.3 Microwave-Assisted Technique
- •3.4 Chemical Oxidation Synthesis
- •4. Properties of Carbon-Based Nanostructured Materials
- •4.1 Thermal Properties
- •4.2 Mechanical Properties
- •4.3 Optoelectronic Properties
- •4.4 Antimicrobial Properties
- •4.5 Biological Properties
- •5. Applications of Carbon-Based Nanostructured Materials
- •5.2 Antibacterial and Antiviral Applications
- •5.3 Theragnostic
- •5.4 Wound Healing
- •5.5 Tissue Engineering
- •5.6 Drug Delivery
- •5.7 Biosensing
- •6. Challenges and Future Perspectives
- •7. Concluding Remarks
- •References
- •Drug Delivery System and Technologies
- •1. Introduction
- •2. Drug Delivery System
- •2.1 Conventional Drug Delivery System
- •2.2 Advanced Drug Delivery System
- •2.3 Controlled and Sustainable Drug Delivery System
- •3. Drug Delivery Technologies
- •3.1 Active and Passive Drug Delivery
- •3.2 Smart Drug Delivery
- •3.3 Intravenous and Extravaneous Drug Delivery
- •3.4 Various Types of Delivery Technologies
- •4. Challenges and Future Perspectives
- •5. Conclusion
- •References
- •Carbon-Based Nanomaterials for Drug Delivery: Past, Present, Future Directions
- •1. Introduction
- •3. Current Status in Drug Delivery by CNMs
- •3.1 Graphene-Based Nanomaterials in Drug Delivery
- •3.4 Nanodiamond Based Drug Delivery Systems
- •3.5 Nano-Onions in Drug Delivery
- •3.6 Nanohorns in Drug Delivery
- •3.7 Fullerene in Drug Delivery
- •4. Challenges and Future Perspective
- •5. Conclusions
- •References
- •Carbon Nanomaterial-Incorporated Supramolecular Drug Delivery
- •1. Introduction
- •2. Different Carbon Nanomaterials in Drug Delivery
- •2.1 Carbon Nanotubes (CNTs)
- •2.3 Graphene
- •2.4 Carbon Quantum Dots
- •2.5 Fullerene
- •2.6 Carbon Nanohorns
- •2.7 Carbon Nano-Onions
- •2.8 Nano-Diamond
- •3. Supramolecular Chemistry in Drug Delivery
- •3.1 Principles of Supramolecular Chemistry
- •3.3 Applications of Supramolecular Biomaterials
- •4. Carbon Nanomaterial-Incorporated Supramolecular Drug Delivery
- •5.1 Cyclodextrins
- •5.2 Calixarenes
- •5.3 Cucurbituril
- •5.4 Pillarenes
- •5.5 Crown Ether
- •6. Toxicity Concerns of Carbon Nanomaterials
- •7. Improving the Effectiveness of Nanoparticle Systems
- •8. Future of Nanomedicine
- •9.1 Challenges
- •9.2 Future Perspectives and Opportunities
- •9.3 Conclusions
- •References
- •Carbon Nanomaterial-Based Polymeric Nanocomposites for Drug Delivery
- •1. Introduction
- •2.1 Carbon Quantum Dot-Based Polymer Nanocomposite
- •2.2 Carbon Nanotube-Based Polymer Nanocomposite
- •2.3 Graphene Quantum Dot-Based Polymer Nanocomposite
- •2.5 Fullerene-Based Polymer Nanocomposite
- •2.6 Nanodiamond-Based Polymer Nanocomposite
- •3. Drug Delivery Systems Using Carbon Nanomaterial
- •3.1 Anticancer Drug Delivery
- •3.3 Infectious Disease Drug Delivery
- •3.4 Topical Drug Delivery
- •3.5 Brain Drug Delivery
- •3.6 Oral Drug Delivery
- •4. Challenge and Future Perspectives
- •5. Conclusion
- •References
- •Carbon Nanomaterial-Incorporated Polysaccharide-Based Nanocomposite for Drug Delivery
- •1. Introduction
- •1.1 Drug Delivery
- •1.2 Carbon Nanomaterials
- •1.3 Polysaccharide-Based Nanocomposite
- •2.1 CN-Incorporated Alginate-Based Nanocomposite
- •2.2 CN-Incorporated Cellulose-Based Nanocomposite
- •2.3 CN-Incorporated Chitosan-Based Nanocomposite
- •2.4 CN-Incorporated Dextran-Based Nanocomposite
- •2.5 CN-Incorporated Hyaluronic Acid-Based Nanocomposite
- •2.6 CN-Incorporated Starch-Based Nanocomposite
- •2.7 CN-Incorporated Pectin-Based Nanocomposite
- •2.8 CN-Incorporated Guar Gum-Based Nanocomposite
- •2.9 CN-Incorporated Agarose-Based Nanocomposite
- •2.10 CN-Incorporated Carrageenan-Based Nanocomposite
- •2.11 CN-Incorporated Glucomannan-Based Nanocomposite
- •3. Challenges and Future Prospective
- •4. Concluding Remarks
- •References
- •Graphene-Based Nanomaterials for Drug Delivery
- •1. Introduction
- •1.1 Challenges in Conventional Drug Delivery Systems
- •1.2 Overview of Nanomaterials for Drug Delivery
- •1.3 Role of Graphene-Based Nanomaterials in Drug Delivery
- •2. Synthesis of Graphene
- •2.1 Chemical Reduction Method
- •2.2 Thermal Reduction
- •2.3 Electrochemical Reduction
- •2.4 Chemical Vapor Deposition Method
- •2.5 Mechanical Exfoliation
- •2.6 Epitaxial Growth Method
- •2.7 Growth in Solvothermal and Hydrothermal Systems
- •2.8 Electrochemical Deposition
- •3. Types of Graphene-Based Materials
- •3.1 Graphene Quantum Dots, (GQDs)
- •3.2 Graphene Oxide (GO)
- •3.3 Graphene Nanoribbons (GNRs)
- •3.4 Oxidized Graphene Nanoribbons
- •4. Graphene Functionalized Materials for Drug Delivery
- •4.1 In Bone Tissue Regeneration
- •4.2 In Neural Regeneration
- •4.3 In Photodynamic and Photothermal Therapy
- •4.4 In Enhancing Cellular and Humoral Immunity
- •4.6 Miscellaneous
- •5. Challenges and Future Perspective
- •6. Conclusion
- •References
- •Carbon Quantum Dots Based Materials for Drug Delivery
- •1. Introduction
- •2. Synthesis Process of Carbon Quantum Dots
- •2.1 Top-Down Approaches
- •2.2 Bottom-Up Approaches
- •2.3 Microwave-Assisted Method
- •2.4 Electrochemical Method
- •2.5 Laser Ablation Method
- •2.6 Pyrolysis Method
- •2.7 Template-Assisted Method
- •4. Challenges and Future Perspective
- •5. Concluding Remarks
- •References
- •Carbon-based Nanocarriers for Sustained Drug Release in Dentistry
- •1. Introduction
- •2.1 Oral Mucosa Structure
- •2.2 Sites for Drug Delivery
- •2.3 Permeability
- •3. Local Drug Delivery for Dental Diseases
- •3.1 Odontogenic Infection
- •3.2 Non-odontogenic Infection
- •4. Bio-adhesive Nanoparticles: Novel Treatment Modality
- •4.1 Bio-adhesive Nanoparticles
- •4.2 Mechanism of Bioadhesion
- •5.1 Carbon Nanotubes
- •5.2 Graphene
- •5.3 Nanodiamonds
- •5.4 Fullerenes
- •5.5 Porous Carbon
- •5.6 Carbon Dots
- •6. Drug Delivery Systems Based on CBNs
- •6.2 Immediate Drug Delivery System (IDDS)
- •6.3 Sustained-release Drug Delivery Systems
- •6.4 Controlled Drug Delivery System (CDDs)
- •8. Conclusion
- •References
- •Fullerene Based Materials for Drug Delivery
- •1. Introduction
- •2. Types of Fullerene Derivatives
- •2.1 Exohedral Fullerene Derivatives
- •2.2 Endohedral Fullerene Derivatives
- •2.3 Surface Derivatized Fullerenes
- •3. Interaction of Fullerene Derivatives for Drug Delivery
- •4. Fullerene Based Materials for Drug Delivery
- •4.1 Nucleic Acid Delivery
- •4.2 Peptide Delivery
- •4.3 Topical Drug Delivery
- •4.4 Infectious Diseases Drug Delivery
- •4.5 Anticancer Drug Delivery
- •4.7 Brain Drug Delivery
- •4.8 Ocular Drug Delivery
- •5. Challenges and Future Perspectives
- •6. Concluding Remarks
- •6.1 Abbreviations
- •References
- •Graphene Quantum Dots-based Nanomaterials for Drug Delivery
- •1. Introduction
- •2. Synthesis of GQDs
- •3. GQD’s Properties for Drug Delivery
- •3.1 Optical Properties
- •3.2 Physicochemical Properties
- •3.3 Mechanical Properties
- •3.4 Biocompatibility and Cytotoxicity
- •4. Characterization of GQDs-Based Nanomaterials
- •4.1 Characterization of Multifunctional GQDs-Based Nanomaterials
- •5.1 Strategies for Developing Medication Delivery Systems Based on GQD
- •5.2 PH-responsive Drug Delivery Systems (GQD-DDSs)
- •5.3 Targeted Drug Delivery Using Ligand-Based GQDs as a Mediator
- •5.4 Improvement of Medicines’ Pharmacological Properties Using GQDs
- •5.5 Enhancing Cytotoxicity with GQD-DDS
- •7. Applications of Chiral GQDs
- •10. Challenges and Future Perspectives
- •11. Conclusions
- •References
- •Carbon Nano-onions for Drug Delivery
- •1. Introduction
- •2. Carbon Nano-Onion: A Multi-Layered Nanocarrier
- •3. Synthesis of Carbon Nano-Onions
- •3.1 Annealing Method
- •3.2 Carbon Ion Implantation Method
- •3.3 Arc Discharge Method
- •3.4 Carbon Vapour Deposition Method
- •3.5 Pyrolysis Method
- •6. Carbon Nano-Onions in Drug Delivery
- •6.1 Delivery of Therapeutic Agents
- •6.2 Delivery of Targeting Agents
- •6.3 Delivery of Imaging Agents
- •7. Challenges and Future Perspectives
- •8. Concluding Remarks
- •References
- •Chitosan/Carbon Nanocomposites in Drug Delivery and Cardiovascular Diseases
- •1. Introduction
- •1.1 Drug Delivery
- •1.2 Cardiovascular Diseases
- •1.3 Chitosan and Its Properties
- •1.4 Chitosan/Carbon Nanocomposites
- •2. Chitosan/Carbon Nanocomposites in Drug Delivery
- •3. Chitosan/Carbon Nanocomposites in CVDs
- •3.1 Chitosan-Based Scaffolds
- •3.2 Chitosan in Cardiac Tissue Engineering
- •3.3 Chitosan-Based Cell Therapy
- •3.4 Chitosan-Based Gene Delivery
- •3.5 Chitosan-Protein Interaction
- •4. Challenges and Future Perspective
- •5. Concluding Remarks
- •References
- •Graphene Reinforced Chitosan Nanocomposites for Drug Delivery
- •1. Introduction
- •2. Chitosan: Structure and Properties
- •3. Graphene: Structure, Types and Properties
- •4.1 Electrospinning Method
- •4.2 Sol–gel Method
- •4.3 Solution Mixing Method
- •4.4 In-situ Polymerization Method
- •5.2 Chitosan/Graphene Aerogels
- •5.3 Chitosan/Graphene Hydrogels
- •5.4 Chitosan/Graphene Thin Films
- •6.1 Oral Drug Delivery
- •6.2 Mucosal Drug Delivery
- •6.3 Transdermal Drug Delivery
- •6.4 Parenteral Drug Delivery
- •7. Challenges and Future Perspectives
- •8. Concluding Remarks
- •References
- •1. Introduction
- •2. Functionalization of CNFs
- •2.1 The Need for Functionalization

Graphene Quantum Dots-based Nanomaterials for Drug Delivery 365
4 Characterization of GQDs-Based Nanomaterials
One of the most crucial photophysical metrics when describing luminous materials
is the quantum yield (QY) [27]. To fine-tune the proposed sensing system, the QY of
all these systems has been examined across a broad spectrum of conditions, including
temperature, concentration, time, and pH (Fig. 12.2a–d). As shown in Fig. 12.2,the
computed values of QY do not change sequentially. This provesthe proposed strategy
can be applied in various settings beyond this research. According to the study, BGQDs have a high QY, but because of their lower stability, their QY has decreased.
Co-doped GQDs with enhanced strength showed improved QY [28]. Further, GQD
has been functionalized with various chemical for their implementation in biomedical
applications [18, 27, 30–35].
4.1 Characterization of Multifunctional GQDs-Based Nanomaterials
As shown in Fig. 12.3A, the XRD is utilized to evaluate the degree of crystallinity of
the manufactured materials. In Fig. 12.3B, we have a representation of the particle
Fig. 12.2 For QYs screening, a three-dimensional graphic depicts multiple physical factors, such as
a temperature, b concentration, c duration, and d the influence of pH. Reproduced with permission
from Royal Society of Chemistry [29]

366 M. Emamul Kabir et al.
shape of the as-synthesized materials. Figure 12.3Ba–e demonstrates that at 10,000
magnifications, N0, N1, N2, N3, and N4 formed thin leaf-like assemblies with wrinkles and random forms due to the layered structure of graphene. Therefore, as illustrated in Fig. 12.3B (f), N4 is observed to be flake-like nanoplatelets under 30,000
magnifications. These findings corroborate those in graphite particles, including tiny,
platelet-like carbon crystals [21]. Figure 12.3C shows the as-synthesized materials’
microstructure and average diameter. As synthesized, the average size of the nanoparticles is 2.6, 2.5, 2.5, 2.1, and 2.0 nm for N0, N1, N2, N3, and N4. In conclusion, the
N-tamper with GQDs was effectively synthesized, and the hydrothermal method of
nitrogen doping had no discernible effect on the morphology or structure of GQDs.
Fig. 12.3 GQD and N(1,2,34)-doped GQD (4.2 g of citric acid (as the carbon-graphene source)
and urea (as the nitrogen doping) in varying quantities of 3.6, 4.2, 5 and 5.6 g were designated
as N1, N2, N3, and N4, respectively) (A) XRD patterns. Micrographs taken with a FE-SEM at
10,000 × and 30,000 × magnification of N0, N1, N2, N3, and N4-doped GQDs, respectively (B).
Comparison (C)HR-TEM images and particle size distribution c urves between a N0-doped GQDs,
b N1-doped GQDs. c N2-doped GQDs, d N3-doped GQDs, and e N4-doped GQDs. Reproduced
with permission from Elsevier [36]

Graphene Quantum Dots-based Nanomaterials for Drug Delivery 367
5 Various Methods for Designing GQDs-Based Drug
Delivery System
5.1 Strategies for Developing Medication Delivery Systems Based on GQD
Many researchers have made GQDs multipurpose drug vehicles. Because of its
special characteristics, it can serve as a nanoparticle host for both organic and inorganic molecules. This enhances targeted drug delivery, controlled/sustained drug
release, infected cell cytotoxicity, drug loading capacity, bioavailability, and biocompatibility [37]. GQD-based DDS (GQD-DDS) uses numerous methods to provide
the greatest results with the least systemic toxicity dependent on therapy needs and
drug cell lines. GDQs can now efficiently transport medications to cells and tissues
based on pH, ligands, and redox potential.
5.2 PH-responsive Drug Delivery Systems (GQD-DDSs)
The pH of the body’s organs and tissues varies widely, from about 1.5 (acidic) in
the bottom stomach area to about 7.5–8 (basic) in the small intestine. Enzymes, the
metabolism of food and medications, and the preservation of homeostasis all rely on
a stable pH level. pH-sensitive GQD-DDSs use this for precise drug administration.
They promote autophagy and destroy infected cells by transporting chemotherapy
medicines to acidic cells and other tumor cell compartments [38, 39]. The metabolic
byproduct lactic acid, frequently found in tumor cells, causes cancer cells to become
more acidic. As a result, their pH levels are below that of healthy cells [40]. GQDs
are ideal drug delivery vehicles because of their distinct physicochemical features,
which allow for controlled drug release at pH-dependent segments. GQDs deliver
doxorubicin and other standard anti-cancer drugs to tumors. Hydrogen bonds connect
the medicine and carrier. These two DDS units vary in depth and connections in
acidic, basic, and neutral conditions. GQD, carboxylic, and amine functional groups
interact strongly at high pH. The medicine is not released at neutral or basic places.
Functional groups connecting with hydrogen ions in acidic environments weaken
the medication-GQD connection. When loaded with DOX, a pH-sensitive, traceable
GQD-DDS releases the drug much faster due to its lower stability [41]. An intelligent
DDS based on GQDs-Fe
acterized in the study above to increase the efficacy of curcumin, a non-poisonous
and aquaphobic anticancer agent. Dissolving GO yielded GQDs co-precipitated with
in a single step to make the GQDs-Fe3O4nanocomposite. The nanoparticles
Fe
3O4
were easily separated using a magnet. The nanocomposite now contains folic acid
that is functionalized by folic acid was devised and char-
3O4

368 M. Emamul Kabir et al.
Fig. 12.4 Synthesis and loading of curcumin onto GQDs-Fe3O4. Reproduced with permission
from Elsevier [42]
chemically linked to it via Carbodiimide/N-hydroxysuccinimide (EDC/NHS) activators. The release mechanism of curcumin was studied at pH values of 5.5 and 7.4
(Fig. 12.4) to delve into the pH sensitivity of the synthesized nanosystem [41].
5.3 Targeted Drug Delivery Using Ligand-Based GQDs as a Mediator
GQD has gained popularity recently due to its adaptable qualities and lower toxicity.
A better solution to the problem of free medicines’ lack of specificity may be found in
ligand-based cells targeting GQD-DDSs. Multiple reactive centers on the surface of
GQDs allow for covalent and non-covalent conjugations with monoclonal antibodies,
ligands, complement factors, vitamins, proteins, and more. Functionalizing GQDs
boosts the drug’s efficiency and specificity for its intended target. Many receptors,
often as many as 100 to 300 times, not less, on a normal cell surface [43], are found
on the extracellular plane of tumor cells, aiding the ligand-based approach. Increased
sensitivity of tumor cells to GQD-DDSs delivering ligands that conjugate to these
receptors is caused by this factor. Examining the nano-bio border is crucial to comprehend the operation of a ligand-based GQD-DDS. This requires the dynamic interplay
of the tumor microenvironment, the oncogenic cells of interest, and the cellular level

Graphene Quantum Dots-based Nanomaterials for Drug Delivery 369
[44]. Due to receptor-mediated endocytosis, DDS accumulates inside cancer cells
after binding to the overexpressed receptor. Quantum dots with conjugated ligands
on their surfaces are taken up by target cells via phagocytosis. Internalization of the
GQD-DDS follows a s ignaling cascade initiated by ligand recognition. Tumor cells
take up the vesicles, which carry the medication inside the cell, where it can target
specific organelles and disrupt their function. This results in the dissociation of the
ligand-receptor complicated [45].
5.4 Improvement of Medicines’ Pharmacological Properties Using GQDs
Any nano-conjugated drug aims to address a shortcoming of the free drug. Therapeutic pharmaceutical applications, including bioavailability, cellular medicine
absorption, drug solubility,and cytotoxicity, can all benefit from GQDs’ varied nanostructure. Extensive study of GQDs has led to their use in treating cancer, diabetes,
and bacterial infections.
5.5 Enhancing Cytotoxicity with GQD-DDS
Drugs used to treat cancer, such as DOX and docetaxel, can penetrate cancer cell
membranes and induce cytotoxicity by suppressing vital cellular functions, including
translation and replication, effectively halting the production of DNA and RNA [38].
To be more precise, these medications damage the DNA structure by inserting themselves between two base pairs. Inside the cells, they undergo a similar reduction to
radicals, becoming capable of cleaving DNA. Due to their systemic toxicity and nonspecific nature, these medications have low drug solubility and severe side effects,
which reduces their efficacy. Confocal laser scanning microscopy (CSLM) was used
to compare the fluorescence intensity of cells treated with DOX either unconjugated
or conjugated with GQDs, and they found no significant difference between the
two treatment groups. From the CSLM pictures, they deduced that the DDS facilitated better drug uptake and accumulation in nuclei [ 46]. According to this study
[47], GQD conjugation lowers the movement of energy free of the drug itself across
the nuclear lipid bilayer, increasing accumulation. Drug-DNA interaction improves
cleavage rates, but the drug-conjugated quantum dot dissociates in the cell. To get
to the nuclei, the nano-drug carrier sidesteps internalization routes that cancer cells
would use to block the anti-cancer medicine. Most of these agents enter cells via
Receptor, clathrin-, or caveolae-mediated endocytosis and then cause cytotoxicity
to tumor cells once they reach the nuclei. GQD-DOX conjugation increases cytotoxicity [47] in two ways: via targeted drug administration and augmentation of

370 M. Emamul Kabir et al.
DNA cleavage activity. Materials, targeted cells, size and drug loading efficiency are
described below based on previous studies (Table 12.2)[15].
6 Progress of GQDs for Effective and Efficient Drug
Delivery (Chirality of GQDs)
Graphene nanosheets’ aquaphobic and van der Waals connections with the sEV lipid
bilayer make them favorable drug transporters for intercalation [55]. Easy adsorption
of hydrophobic pharmaceuticals is made possible by graphene’s delocalized electron, and hydrophilic medications can be effectuated completely onto the material.
Despite this, graphene drug carriers frequently become imprisoned within the bilayer,
never reaching the interior. Recent research [56–58] identified interaction based on
chirality between the sheets of graphene and the lipid molecules as a putative mechanism allowing this concluding passage into the interior of the sEVs. Chirality is a
fundamental property of all living organisms, [59] making it an important factor in
the biomedical uses of nanoparticles (NPs) involving cellular absorption, immunological response, and tissue transport [60]. Because of their low cytotoxicity, great
biocompatibility [61], optical characteristics [25], and finely controlled properties
related to physical and chemical, GQDs have found widespread use in biomedical
applications [62]. Specifically, the zero-dimensional (0D) architecture, nanoscale
dimensions, and chemical structure [63] of GQDs enabled them to exhibit excellent
passive transport properties via cellular lipid membranes [61]. Furthermore, GQDs
can efficiently transport a wide variety of pharmaceuticals (>90%) through pi loading
and van der Waals connections; these drugs can be chemical, hydrophilic, biological,
or hydrophobic [31, 64]. Since sEVs have lipid bilayers comparable to their parent
cells’ membranes, one that is right-handed and chiral could be a useful tool for
efficiently loading drugs/genes into sEVs via passive transport [65, 66]. Successful
production of a GQD dispersion was observed, with particles ranging in size from
2–7 nm and emitting vivid yellow photoluminescence (PL, Fig. 12.5). EDC/NHS
cross-connecting method was used to covalently fix L-cysteine/D-cysteine moieties
to the boundaries of the carbon pieces; [67]Fig.12.5a denotes L- and D-GQDs,
which are the corresponding products. TEM scans demonstrate that unmodified and
modified GQDs have a similar size distribution in the 2–7 nm range (Fig. 12.5b,c)
[68]. PL spectra also undergo spectral shifts simultaneously. Robust release at 520–
550 nm is seen in the pristine, L, and D-forms of GQDs when they are stimulated by
photons with ex = 330 nm (Fig. 12.5d–f).

Table 12.2 Materials, targeted cells, size and drug loading efficiency. Adapted and reproduced with permission form ACS [15]
Materials; targeted cells Drug Medication
loading
GQD-Cyc-HCl;L929 cells,
BHC 0.2 mg/mL 5 – 5.8 ∼50 24 ∼50 [48]
Diameter
(nm)
Drug
loading pH
Drug
release pH
Release % Time of
release (h)
Cell
viability %
Reference
HeLa and MDA-MB-231
cells
N-GQD;MCF-7 Methotrexate 10 mg/mL 7–17 7.4 7.4 60 9 ∼80 [49]
GdGQDs;HeLa cells DOX 80 wt % – 7.4 7.0 12 6 >90 [50]
FA-GQD;HeLa, A549,
DOX 68 wt % 1–4 – 5.5 – 8 >80 [51]
HEK293A
GQD-biotin;A549 DOX 16.6 wt % <5 7.4 5.3 burst 0.08 85 [52]
GQD-PEG; DOX 2.5 (mg/mL) 15 7.4 5.5 42 6 – [53]
N-GQDs-APTES;nucleus DOX 10 (mg/mL) 4 – 5.7 42.5 24 17 [54]
GQD-RGD;U251 glioma
DOX 5(mg/mL) 3.7 – 5.0 40.1 72 70.9 [8]
cells
Graphene Quantum Dots-based Nanomaterials for Drug Delivery 371

372 M. Emamul Kabir et al.
Fig. 12.5 Chiral GQD synthesis molecular diagrams a A little piece of the GQD graphene sheet is
seen, Dispersion pictures of b D-GQD and L-GQD c captured by TEM, d original, e L-GQD, and
f D-GQD dispersion photoluminescence spectra in room temperature. Photographs of the relevant
dispersions under UV light with a maximum wavelength of 365 nm are included as insets in panels
d, e,andf. Reproduced with permission from American Chemical Society [56]
7 Applications of Chiral GQDs
Among the known loading technologies, the minimum invasive is incubation as
a passive method of exogenous loading of medicines and harvested sEVs [69].
Passive loading effectiveness of soluble medicines is typically below 10% without
the conjugation of hydrophobic moieties [70, 71]. Medication loading efficiencies
of 66.3% and 64.1% for siRNA and DOX were achieved by optimizing the GQD
size and ligands to maximize their chirality [58]. They initially produced chiral
GQDs resulting from surface change with L/D-cysteine (L- and D-CysGQDs) using
a formerly published approach to study the penetration efficiency of chiral GQDs
into sEVs (Fig. 12.6a,b). L- and D-CysGQDs were found to have a distribution of
sizes of 3.0–9.4 nm, as observed in images in TEM (Fig. 12.6c). The size variety of
L- and D-Cys-GQDs in TEM was authenticated by AFM pictures (Fig. 12.6d). The
AFM results (Fig. 12.6d) established that the thickness of L- and D-Cys-GQDs were
within 2 nm, which is reliable with a layer of chiral GQDs with improved height due
to helical clasping (twisting) of the pristine GQDs (1 nm). Positive and negative peaks
at 236 nm were seen in the L- and D-CysGQDs CD spectra, respectively (Fig. 12.6e).
In addition, they exhibited some loosening of exciton confinement[56]. Charge transport between the graphene carbon core and functional groups of GQDs narrows the
band gap [72, 73], causing a redshift of 26 nm. Confocal microscopy revealed that

Graphene Quantum Dots-based Nanomaterials for Drug Delivery 373
chiral GQDs had entered sEVs when their inherent fluorescence (at about 525 nm,
denoted as blue) accumulated within the cells. Under the same sEVs concentration (108 particles/mL), right-handed chirality Cys-GQDs (D-Cys-GQDs) displayed
a substantially larger density of blue dots (the aggregation of GQDs) compared
to achiral R-Cys-GQDs and left-handed L-Cys-GQDs (Fig. 12.6f). Accumulation
and permeation of D-Cys-GQDs in the sEVs were revealed by the colocalization
of D-Cys-GQDs (blue) and PHK26-labeled sEVs (red) in Fig. 12.6g. To sum up,
the amount of GQD-loaded sEVs (blue dots larger than 30 nm as a threshold) was
compared to the total counts of sEVs via nanoparticle tracking analysis (NTA) to
establish the permeation efficiency of GQDs in sEVs (Fig. 12.6h). Importantly, TEM
and NTA data show that the size and shape of sEVs were unchanged after the loading
operation by D-Cys-GQDs (Fig. 12.6i). D-Cys-GQDs were found to have a greater
tendency to permeate mammalian cells’ cellular lipid membrane than L-Cys-GQDs,
consistent with prior findings via molecular dynamics (MD) simulation [56].
8 Applications of GQDs-Based Nanomaterials for Drug
Delivery
Researchers have used confocal-type fluorescence microscopy to visualize chiral
GQD’s colocalization (blue), sEVs (membrane dye in green), and Dox (red) to evaluate drug l oading via sEVs. To load the chemotherapeutic medication doxorubicin
(Dox) onto sEVs. D-Cys-GQDs. A schematic shows how D-Cys-GQDs make loading
with Dox easier for sEVs (Fig. 12.7a). Reducing efficiency and fluorescence spectra
(max = 360 nm) were used to characterize the direct addition of Dox (200 M)
onto the D-Cys-GQDs (7.5–22) (Fig. 12.7b). In confocal pictures, Dox lowered the
signal strength of the blue signals corresponding to the distinct GQDs changes due
to the FRET effect. Thus, chiral-GQDs/Dox complex permeability was examined
using the red Dox channel (Fig. 12.7c). Based on liposome formulation, sEV drug
loading efficiency is the percentage of active sEVsencapsulating medications [73].
D-Cys-GQDs loaded into sEVs more efficiently (66.7 9.5%) than L-Cys/Dox (18.3
6.7%). R-Cys-GQDs/Dox exhibited the lowest loading efficiency (15.2% 6.3%) of
any sample (Fig. 12.7d). A control group of sEVs with conventionally sonicated Dox
was also created. Confocal fluorescence microscopy (Fig. 12.7c) demonstrated that
conventional sonication (14.5 7.9%) stacks poorly. D-Cys-GQD drug loading did
not significantly change sEV size or cell integrity. They treated 3T3 cells with sEVsDox for 24 h in vitro and compared them to a control group treated with free Dox to
determine if they could take up D-Cys-GQDs/Dox-loaded sEVs. Dox is thought to
exert its impacts via the embolism of DNA and protein-DNA interactions in replication and transcription [74]. Dox signals (red) in confocal images showed that Dox
molecules entered cells and aggregated in the nucleus (Fig. 12.7e). D-Cys-GQDs
(blue) were mostly in the cytoplasm of cells, showing that Dox was released from
the complex without a drug release mechanism. These benefits enable compact and

374 M. Emamul Kabir et al.
Fig. 12.6 a The theory behind i mproving medication loading into sEVs with chiral GQDs. b Asymmetric nanopore membrane (ANM) images captured by TEM of isolated sEVs. c TEM images of
R-, l-, and d-Cys-GQDs, and TEM characterization of d-Cys-GQDs after 1 week of sample preparation. d AFM, and e circular dichroism (CD). f A confocal microscope analysis was performed
at room temperature to assess the permeation of chiral GQDs (blue) into sEVs. Under the guidance of a 100 kDa centrifuge tube, samples were generated by incubating 7.5 M achiral or chiral
GQDs with 3T3 sEVs (1.0 109 particles/mL), followed by four washes in PBS (4 °C). After exposure to d-Cys-GQDs (blue), PHK26-labeled sEVs were imaged using confocal microscopy (red).
g After being exposed to d-Cys-GQDs (blue), PHK26-labeled sEVs were imaged using confocal
microscopy (red). h The percentage of sEVs loaded with GQDs (blue) relative to the total number
of sEVs was used to calculate the infusion efficiency. i Using nanoparticle tracking analysis (NTA),
the distribution of size and number of particles of GQD-loaded sEVs were determined. Reproduced
with permission from the American Chemical Society [58]
versatile drug-release monitoring devices [75]. Then, researchers looked at sEVsDox’s capacity to stop the spread of cancer cells in the lab. Negative controls include
untreated cells, cells got treatment with control sEVs, and D-Cys-GQDs mixed with
free Dox. sEVs-Dox was used to treat cervical cancer (HeLa) cells and human hepatocellular carcinoma (HepG2) for 24 h. The CCK-8 test was used to determine the
Соседние файлы в папке Библиотека им академика М.И. Перельмана
